Information about Solifenacin
Liver safety of Solifenacin
Solifenacin has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Solifenacin
Solifenacin (soe" li fen' a sin) is an anticholinergic agent that inhibits muscarinic actions of acetylcholine on autonomic nerve endings, decreasing secretions and inhibiting gastrointestinal and bladder motility. Solifenacin increases the bladder capacity and decreases contractions and the urgency of urination.
FDA approval information for Solifenacin
Solifenacin was approved for use in the United States in 2004 and it remains in clinical use. Current indications are for treatment of overactive bladder and symptoms of urgency and urinary frequency.
Dosage and administration for Solifenacin
It is available in tablets of 5 and 10 mg under the brand name VESIcare. The recommended adult oral dose is 5 to 10 mg once daily.
Side effects of Solifenacin
Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, restlessness, confusion and hallucinations. anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.
- Overactive bladder syndrome agents - darifenacin, fesoterodine, flavoxate, hyoscyamine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium